News

For people with malignant peritoneal mesothelioma treated with CRS/HIPEC, prognosis may improve as more time passes after surgery. A two-center study found that the estimated chance of surviving another five years rose among patients who had already survived several years. Lower tumor burden and avoiding serious complications were associated with longer survival. The findings offer hope, but they cannot predict an individual patient’s outcome.

A study of 101 patients with peritoneal metastases found that long-term survival was possible after cytoreductive surgery, HIPEC, and postoperative intraperitoneal chemotherapy. Five-year overall survival reached 62% for patients with appendix cancer and 34% for those with colorectal cancer. The results highlight the importance of specialized evaluation and removing all visible disease, but the study was small, conducted at one center, and did not include a comparison group.

Recovering from CRS/HIPEC can bring nutrition challenges that patients and caregivers may not expect. In interviews with 20 colorectal cancer survivors and 10 caregivers, researchers found that diarrhea, early fullness, pain, meal preparation, and changing dietary needs can complicate recovery. The study highlights the value of earlier, ongoing, and individualized nutrition support to help patients and caregivers feel better prepared for life after CRS/HIPEC.

A new study followed 111 patients with pseudomyxoma peritonei (PMP) for one year after cytoreductive surgery (CRS) and HIPEC. Quality of life declined most during the early weeks after surgery, with fatigue, pain, appetite loss, sleep difficulties, and other symptoms affecting recovery. Most measures improved steadily and returned to or approached pre-surgery levels within 6–12 months, offering patients and caregivers valuable insight into what recovery may look like.

A new multi-institutional study found that a second cytoreductive surgery (CRS) with or without HIPEC may be a safe option for carefully selected patients with recurrent colorectal cancer that has spread to the peritoneum. Patients who underwent repeat surgery had similar complication rates and lived longer than those treated with systemic therapy or supportive care alone.

A new study examined how often incisional hernias occur after cytoreductive surgery (CRS) and HIPEC for colorectal and appendiceal cancers. Researchers found that patients with a history of prior open abdominal surgery or a previous hernia had the highest risk, highlighting the importance of individualized surgical planning, recovery, and long-term follow-up.

PIPAC is a newer way to deliver chemotherapy directly to cancers that have spread to the lining of the abdomen. Using a minimally invasive procedure, chemotherapy is sprayed as a fine mist to improve drug delivery while reducing side effects. Learn how PIPAC works, who may benefit, how it differs from HIPEC, and why it is being studied in clinical trials.

Peritoneal metastases are difficult to treat because standard IV chemotherapy often cannot reach tumors inside the abdomen effectively. This review explores NIPS, an approach that combines intravenous chemotherapy with repeated chemotherapy delivered directly into the abdominal cavity. Early research—especially in gastric cancer—suggests this strategy may improve disease control, increase eligibility for surgery, and help some patients live longer.

International experts are working to make treatment for advanced ovarian cancer more personalized. This special issue of PSOGI World News highlights new evidence supporting careful patient selection for cytoreductive surgery and HIPEC, the growing role of minimally invasive surgery, and how emerging technologies like artificial intelligence may improve treatment planning and outcomes in the future.

The CHARLIE-2 trial is the first randomized study to directly compare HIPEC and PIPAC, two methods of delivering chemotherapy directly into the abdomen for patients with peritoneal carcinomatosis. Researchers will evaluate safety, quality of life, treatment response, and cost to determine which approach may provide the greatest benefit for patients who are not candidates for complete tumor-removal surgery.

Genetic mutations may determine which ovarian cancer patients do better following HIPEC

Pancreatic cancer that has spread to the lining of the abdomen (called the peritoneum) is often difficult to treat and is associated with poor outcomes. Standard treatment typically involves chemotherapy, but survival rates remain low. Researchers conducted a systematic review to examine whether a treatment approach called cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) may improve outcomes for some patients with pancreatic cance

Peritoneal metastases occur when cancer spreads to the lining of the abdomen (the peritoneum). This can happen with cancers such as colorectal, appendiceal, gastric (stomach), ovarian cancers, and peritoneal mesothelioma. Historically, patients with peritoneal metastases had very limited treatment options and poor survival. Researchers reviewed published studies to better understand how a treatment called cytoreductive surgery combined with HIPEC affected survival.

In the fight against advanced abdominal cancers, we stand behind a powerful treatment that is changing outcomes and saving lives: CRS/HIPEC (Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy). This life-extending procedure offers renewed hope for patients with complex peritoneal surface malignancies. And yet far too many never hear about it in time. The Abdominal Cancers Alliance is here to support patients in their fight.

Framarini M, D'Acapito F, Lippolis PV, Di Giorgio A, Di Pietrantonio D, Sommariva A, Sammartino P. Expanding the role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study on uncommon peritoneal malignancies. World J Clin Oncol 2025; 16(12): 112443 [PMID: 41480175 DOI: 10.5306/wjco.v16.i12.11244 3] Peritoneal metastasis is when cancer cells spread from the stomach or other organs to the lining of the abdominal cavity. This type of sprea

This research study explored outcomes for people with colorectal cancer that had spread to two places at the same time: the lining of the abdomen (called the peritoneum), and the liver.